Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-5525 +/- Pembrolizumab in Advanced Solid Tumors
NCT06960395Phase 1Recruiting
- Sponsor
- Vir Biotechnology
- Start
- Jul 2025
- Primary completion
- Aug 2029
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of SAR446368 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more (4 arms), sponsored by Vir Biotechnology. Primary endpoints: Primary Safety Objectives up to 52 months and Primary Efficacy Objectives up to 52 months. Started Jul 2025; status: recruiting.
02
Drugs
SAR446368
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06960395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06960395.